Targeted prodrug design to optimize drug delivery

Area of Science:

• Drug Delivery and Pharmaceutical Sciences
• Biotechnology and Genetic Engineering
• Oncology Therapeutics

Background:

• Classical prodrugs often lack specificity, leading to undesirable side effects and limited efficacy.
• Targeted prodrug design emerges as a sophisticated strategy for enhancing drug delivery precision.
• Addressing limitations in bioavailability, site specificity, and chemical stability is crucial for effective therapeutics.

Purpose of the Study:

• To review evolving strategies in targeted prodrug design for improved drug delivery.
• To highlight the potential of enzyme or transporter-targeted prodrugs in cancer chemotherapy and oral delivery.
• To explore the synergistic use of gene delivery with targeted prodrugs.

Main Methods:

• Review of current literature on targeted prodrug strategies.
• Analysis of enzyme- and transporter-mediated prodrug activation mechanisms.
• Discussion of gene-directed enzyme prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT).

Main Results:

• Targeted prodrugs demonstrate significant potential for selective drug delivery, particularly in cancer treatment.
• Integration with gene delivery can further enhance site-specific prodrug activation and therapeutic outcomes.
• Specific strategies like ADEPT, GDEPT, and peptide transporter-associated prodrug therapy show promise.

Conclusions:

• Targeted prodrug design represents a significant advancement over classical prodrug approaches.
• Enzyme and transporter targeting, combined with gene delivery, offers a powerful platform for selective and efficient drug therapy.
• These strategies hold promise for improving cancer chemotherapy and oral drug delivery systems.